Diabetes with hypertension medical therapy

Revision as of 16:03, 15 September 2011 by Priyamvada Singh (talk | contribs) (/* Study name:LIFE study, 2002{{cite journal| author=Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U et al.| title=Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reductio)
Jump to navigation Jump to search

Diabetes mellitus Main page

Patient Information

Type 1
Type 2

Overview

Classification

Diabetes mellitus type 1
Diabetes mellitus type 2
Gestational diabetes

Differential Diagnosis

Complications

Screening

Diagnosis

Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]

Overview

Hypertension is a common co-morbidity associated with patients of diabetes, especially type 2 diabetes. Proper management of both these conditions are important to prevent future chronic complications like cardiovascular, nephrology and other complications.

Supportive trial data

Study name:LIFE study, 2002[1]

  • Study design: Double blinded, randomised, parallel-group trial
  • Sample size: 1195 patients with diabetes, hypertension, left ventricular hypertrophy (on electrocardiograms)
  • Drugs: Losartan or Atenolol
  • Study period: 4 years
  • Study results: Losartan was found to be more effective than atenolol in reducing composite endpoints like cardiovascular morbidity and all causes mortality in patients with hypertension, diabetes, and left-ventricular hypertrophy.

Study name: Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, (FACET), 1998 [2]

References

  1. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U; et al. (2002). "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol". Lancet. 359 (9311): 1004–10. doi:10.1016/S0140-6736(02)08090-X. PMID 11937179. Review in: ACP J Club. 2002 Nov-Dec;137(3):87
  2. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G; et al. (1998). "Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM". Diabetes Care. 21 (4): 597–603. PMID 9571349.

Template:WH Template:WS